ROCO
6242
Market cap33mUSD
Oct 06, Last price
33.85TWD
1D
0.00%
1Q
-5.97%
Jan 2017
-11.39%
IPO
127.49%
Name
Li Kang Biomedical Co Ltd
Chart & performance
P/E
12.84
P/S
1.83
EPS
2.64
Div yield, %
5.91%
Shrs. gr., 5y
2.61%
Rev. gr., 5y
5.23%
Revenues
589m
+4.19%
Net income
84m
+8.83%
CFO
88m
+35.27%
Dividend
Jun 16, 20262 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Li Kang Biomedical Co., Ltd. specializes in the development and distribution of nutritional supplements, cosmeceuticals, and health-focused beverages. Beyond its product lines, the company also provides consulting and operational support for tourism factories, and offers telemarketing solutions. Established in 1982, the firm initially operated under the name BAFO Technologies Corporation, before adopting its current moniker, Li Kang Biomedical Co., Ltd., in September 2014. The company maintains its headquarters in Tainan City, Taiwan.
Key people
Yuxiu Zheng
Chairman of the Board, General Manager · since 2017
Liyu Lin
Finance Manager, Corporate Governance Officer · since 2023
Mingju Chen
Deputy General Manager · since 2014
Zhonghua He
Deputy General Manager · since 2012
Bijie Gap
Corporate Governance Officer · since 2025
Yayi Huang
Director · since 2017
Huiqian Li
Director · since 2017
Hongyuan Lin
Director · since 2017
Jianping Zhang
Director · since 2014
Huiyuan Zhang
Director · since 2010
Independent Director · since 2023
Zhilin Chen
Independent Director · since 2023
Independent Director · since 2023
Ruixiang Xu
Independent Director · since 2017
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||